Advertisement

Topics

Immunicum AB IMMU Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

12:49 EDT 17 Apr 2018 | BioPortfolio Reports

Summary


Immunicum AB Immunicum is a biopharmaceutical company that focuses on the development of immunooncology therapies for the treatment of solid tumors. The company's lead development candidate, ilixadencel is in clinical trials for the treatment a range of solid tumors including hepatic cell carcinoma, renal cell carcinoma, and gastrointestinal stromal carcinoma. Its other pipeline programs include SUBCUVAX, Ad5PTDf35 Adenovirusvector and CD70 among others. Immunicum spans its expertise in the development of allogeneic, offtheshelf cellbased therapies. The company works in partnership with academia, biotech and pharmaceutical companies to develop and commercialize new therapeutics. Immunicum is headquartered in Gothenburg, Sweden.


Immunicum AB Key Recent Developments


Feb 16,2018: Immunicum Reports Net Loss Of TSEK18,826 In Fourth Quarter Of 2017

Jan 31,2018: Immunicum Appoints Michaela Gertz As CFO

Jan 31,2018: Michaela Gertz Joins Immunicum as CFO

Jan 09,2018: Immunicum ends patient enrolment for Phase II trial of Ilixadencel

Dec 04,2017: Immunicum Announces Report from the Extraordinary General Meeting on December 4, 2017


This comprehensive SWOT profile of Immunicum AB provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Immunicum AB including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.


The profile contains critical company information including*,


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Note*: Some sections may be missing if data is unavailable for the company.


Key benefits of buying this profile include,


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Original Article: Immunicum AB IMMU Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

NEXT ARTICLE

More From BioPortfolio on "Immunicum AB IMMU Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...